HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57.
September 03, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a high price target of $57 by a reputable analyst suggests a positive outlook for Rigel Pharmaceuticals. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100